Other Updated 2022-01-12

XELJANZ/XELJANZ XR (tofacitinib) – Risk of Major Adverse Cardiovascular Events, Malignancy, Thrombosis and Infection

Recalled Product

XELJANZ/XELJANZ XR (tofacitinib)


Hazard / Issue

New safety information - Product safety

Issued by

Marketed health products

View official government recall

Looking for safe alternatives?

Browse certified-safe products in this category on Amazon Canada →